RenovoRx, Inc. – NASDAQ:RNXT

Add to watchlist

$0.92

-0.38

-29.23%

Market open

Closed in about 6 hours

+0.78%

month

+0.78%

quarter

+30.00%

year

Market Cap	30.00M
Enterprise value	N/A

P/E	-2.88
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	4.18
PEG ratio	0.06
EPS	-0.72

Revenue	N/A
EBITDA	-12.32M
Income	-8.05M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

RenovoRx, Inc. (NASDAQ:RNXT): Profit margin
Jun 2023	0	-2.32M
Sep 2023	0	-1.42M
Dec 2023	0	-3.22M
Mar 2024	0	-1.07M

RenovoRx Financials Estimate

Q Y

RenovoRx, Inc. (NASDAQ:RNXT): Analyst Estimates
Dec 2023	0	-3.22M
Mar 2024	0	-1.07M
Oct 2025	0	-1.49M
Dec 2025	0	-1.49M

Analysts Price target
Financials & Ratios estimates

RenovoRx, Inc. (NASDAQ:RNXT): Earnings per share (EPS)
2023-11-13	-0.3	-0.27
2024-04-01	-0.3	-0.17
2024-05-10	-0.14	-0.07

RenovoRx, Inc. (NASDAQ:RNXT): Debt to assets
Jun 2023	6314000	5.12M	81.18%
Sep 2023	3519000	3.51M	99.83%
Dec 2023	1466000	4.46M	304.64%
Mar 2024	4788000	3.02M	63.1%

RenovoRx, Inc. (NASDAQ:RNXT): Cash Flow
Jun 2023	-2.77M	5.00M
Sep 2023	-2.72M	0
Dec 2023	-2.05M	0
Mar 2024	-2.20M	5.42M

RenovoRx alternative data

RenovoRx, Inc. (NASDAQ:RNXT): Employee count
Aug 2023	10
Sep 2023	10
Oct 2023	10
Nov 2023	10
Dec 2023	10
Jan 2024	10
Feb 2024	10
Mar 2024	10
Apr 2024	10
May 2024	8
Jun 2024	10
Jul 2024	10

RenovoRx
Hedge Funds Holdings Q1 2023

2.52% -19.89%

of RNXT is owned by hedge funds

6 -5

hedge funds hold RNXT stock

131.51K -1.03M

shares is hold by hedge funds

RNXT hedge funds holdings changes

RenovoRx, Inc. (NASDAQ:RNXT): Insider trades (number of shares)
Period	Buy	Sel
Oct 2023	1100	0
Jan 2024	344256	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	26 Jan 2024	AGAH RAMTIN director, officer..	Common Stock	40,983	$1.22	$49,999
Purchase	26 Jan 2024	AGAH RAMTIN director, officer..	Warrants	40,983	$1.22	$49,999
Purchase	26 Jan 2024	SPIEGEL ROBERT J. director director	Warrants	40,983	$1.22	$49,999
Purchase	26 Jan 2024	BAGAI SHAUN director, officer..	Common Stock	40,983	$1.22	$49,999
Purchase	26 Jan 2024	BAGAI SHAUN director, officer..	Warrants	40,983	$1.22	$49,999
Purchase	26 Jan 2024	MACFARLANE K. ANGELA director director	Warrant Shares	40,983	$1.22	$49,999
Purchase	26 Jan 2024	SPIEGEL ROBERT J. director director	Common Stock	40,983	$1.22	$49,999
Purchase	26 Jan 2024	MARTON LAURENCE director director	Warrants	8,196	$1.22	$9,999
Purchase	26 Jan 2024	MACFARLANE K. ANGELA director director	Common Stock	40,983	$1.22	$49,999
Purchase	26 Jan 2024	MARTON LAURENCE director director	Common Stock	8,196	$1.22	$9,999

RenovoRx
Executives

Insider	Age	Since	Compensation
Mr. Shaun R. Bagai (1977) Chief Executive Officer & Director	48		$253,000
Dr. Ramtin Agah M.D. (1966) Founder, Chairman of Board & Chief Medical Officer	59		$120,000

RenovoRx
Latest News

Monday, 30 December 2024
08:00	RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform	businesswire.com
Wednesday, 20 November 2024
08:45	Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial	globenewswire.com
Thursday, 14 November 2024
08:00	RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights	globenewswire.com
Wednesday, 25 September 2024
08:30	RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians	globenewswire.com
Thursday, 19 September 2024
08:30	RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer	globenewswire.com
Tuesday, 27 August 2024
08:30	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York	globenewswire.com
Wednesday, 14 August 2024
08:30	RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial	globenewswire.com
Monday, 8 July 2024
08:30	RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®	globenewswire.com
Wednesday, 26 June 2024
08:30	University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial	globenewswire.com
Monday, 10 June 2024
08:30	RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships	globenewswire.com
Thursday, 30 May 2024
08:30	RenovoRx CEO Issues Update Letter to Shareholders	businesswire.com
Tuesday, 21 May 2024
09:00	Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery	businesswire.com
Tuesday, 14 May 2024
09:00	RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024	businesswire.com
Thursday, 2 May 2024
09:00	RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024	businesswire.com
Thursday, 18 April 2024
08:30	RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement	businesswire.com
Tuesday, 16 April 2024
08:30	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	businesswire.com
Monday, 15 April 2024
08:00	RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026	businesswire.com
Monday, 8 April 2024
13:52	RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023	InvestorPlace
Friday, 5 April 2024
08:30	RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024	Business Wire
Monday, 2 October 2023
08:30	RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023	Business Wire
Friday, 28 April 2023
08:30	RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023	Business Wire
Wednesday, 1 March 2023
08:30	RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023	Business Wire
Wednesday, 25 January 2023
08:30	RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023	Business Wire
Thursday, 19 May 2022
08:30	RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform's Potential Utility for the Treatment of Bile Duct Cancer	Business Wire
Friday, 11 March 2022
08:30	RenovoRx to Participate in March 2022 Investor Conferences	Business Wire
Monday, 6 December 2021
10:00	5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard	Benzinga
Monday, 29 November 2021
14:14	Short Squeeze Stocks: PPSI, NUZE and 3 Others Experts Think Are Ready to Pop	InvestorPlace
09:26	5 Short Squeeze Candidates To Watch: Pioneer Power Tops List Along With Newegg, Nuzee And More	Benzinga
Wednesday, 10 November 2021
15:41	RenovoRx (RNXT) Stock: Why The Price Surged Over 130% Today	Pulse2
10:44	Dear FSR Stock Fans, Mark Your Calendars for an EV Catalyst on Nov. 17	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of RenovoRx stock today?

One share of RenovoRx stock can currently be purchased for approximately $0.92.
When is RenovoRx's next earnings date?

Unfortunately, RenovoRx's (RNXT) next earnings date is currently unknown.
Does RenovoRx pay dividends?

No, RenovoRx does not pay dividends.
How much money does RenovoRx make?

RenovoRx has a market capitalization of 30.00M. RenovoRx made a loss 10.23M US dollars in net income (profit) last year or -$0.07 on an earnings per share basis.
What is RenovoRx's stock symbol?

RenovoRx, Inc. is traded on the NASDAQ under the ticker symbol "RNXT".
What is RenovoRx's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of RenovoRx?

Shares of RenovoRx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are RenovoRx's key executives?
RenovoRx's management team includes the following people:
- Mr. Shaun R. Bagai Chief Executive Officer & Director(age: 48, pay: $253,000)
- Dr. Ramtin Agah M.D. Founder, Chairman of Board & Chief Medical Officer(age: 59, pay: $120,000)
Is RenovoRx founder-led company?

Yes, RenovoRx is a company led by its founder Dr. Ramtin Agah M.D..
How many employees does RenovoRx have?

As Jul 2024, RenovoRx employs 10 workers.
When RenovoRx went public?

RenovoRx, Inc. is publicly traded company for more then 4 years since IPO on 26 Aug 2021.
What is RenovoRx's official website?

The official website for RenovoRx is renovorx.com.
Where are RenovoRx's headquarters?

RenovoRx is headquartered at 4546 El Camino Real, Los Altos, CA.
How can i contact RenovoRx?

RenovoRx's mailing address is 4546 El Camino Real, Los Altos, CA and company can be reached via phone at +65 02844433.

RenovoRx, Inc.

renovorx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

+65 02844433

4546 El Camino Real
Los Altos, CA 94022

CIK: 0001574094
ISIN: US75989R1077
CUSIP: 75989R107